

Rat Peripheral Blood Study Phase Plan (M56MF-2008) for MicroFlow^{BASIC} Analysis Kit

An original signed document is required for sample analysis.

A. Contact Information

Test Facility Name and Address:

Study Director:

Name _____
Phone _____
Fax _____
Email _____

Test Site Name and Address:

Litron Laboratories
200 Canal View Blvd., Suite 106
Rochester, New York 14623
phone: 585-442-0930
fax: 585-442-0934
info@litronlabs.com
www.litronlabs.com

Lead QA Auditor:

Name _____
Phone _____
Fax _____
Email _____

B. Study Information

Study ID: _____

GLP Number: _____
(if not provided, Litron will assign one)

- Initial here if this data will be submitted to a regulatory agency and provide the agency name:_____. Please provide a copy of your protocol prior to sample analysis. For FDA GLP analyses, individual samples must be labeled with the following information: Sample ID, Study ID, Date Collected, Source (i.e., rat) and Type (i.e., Blood). For OECD GLP, label samples with Unique ID and Sample ID. Indicate if the analysis is to be performed according to either FDA and/or OECD GLP. _____
- For Non-GLP analysis, initial here if a final report is requested in addition to the electronic data file.
- Initial here for statistical analysis of data. Additional charges apply. Contact Litron for details.
- Initial here to have study phase specific records sent to your test facility after study phase completion, otherwise records will be retained at Litron (see Section 8).

C. If applicable, please indicate any requested modifications to this Study Phase Plan:

D. Study Phase Plan Approval

Study Director Signature: _____ **Date:** _____

For Litron use only	
Principal Investigator _____	
Principal Investigator's Signature _____	Date _____

1. Objective

This MicroFlow® Study Phase Plan describes procedures for analyzing test facility-prepared rat peripheral blood samples for the presence of micronuclei (MN) using the MicroFlow procedure. Micronuclei will be analyzed in the high CD71-positive reticulocyte (RET) population to provide an indication of genotoxicity. The frequency of high CD71-positive RET (% RET) among total red blood cells (RBCs) is also measured to provide an indication of bone marrow toxicity.

Accumulating data suggests that rat peripheral blood is an adequately sensitive compartment for analyzing micronucleus formation, despite the ability of the rat spleen to destroy micronucleated erythrocytes. Although the MicroFlow method provides valuable information when used with rat peripheral blood, regulatory acceptance of this data should not be assumed. The analysis can be performed under US Food and Drug Administration (FDA) and/or Organisation for Economic Co-Operation and Development (OECD) Good Laboratory Practice (GLP) guidelines (see Section B).

2. Introduction

The *in vivo* Micronucleus Assay is capable of detecting clastogenic (chromosome-breaking) and aneugenic (whole chromosome loss) activity. When cell division occurs, the chromosome fragments or whole chromosomes that are not included in the main nucleus become a micronucleus. Erythrocytes expel their main nucleus before entering the bloodstream, making them ideal for measuring fragmented DNA. Flow cytometry is used for this analysis, as it provides a high-speed method for objective scoring of these rare events. Stained blood cells fluoresce as they pass through a focused laser beam, and the collected data is then sent to a computer for analysis. Micronuclei occur spontaneously, but clastogens and aneugens cause an increase in the number of MN relative to the background (spontaneous) level.

3. Proposed Study Dates

The experimental start and end dates will be documented in the MicroFlow report.

4. Experimental Procedures (performed at Test Facility)

The test facility is responsible for following the procedures detailed in the Litron-provided manual. Substitutions of kit components or deviations from the procedures described in the manual are not recommended. Modifications not previously approved by Litron may result in samples that are incompatible with flow cytometric analysis.

5. Flow Cytometric Analysis (performed at Test Site)

- **Sample Receipt**

Upon receipt at Litron, the fixed samples will be stored in a freezer (-85 °C ± 5 °C) until preparation for analysis.

- **Sample Preparation**

The fixed samples will be washed with a cold, balanced salt solution and isolated by centrifugation. The resulting cell pellets will be stored at 5 °C ± 3 °C or on ice until staining.

- **Staining for Identification of Cell Populations**

Samples will be incubated with RNase (to degrade RNA), a fluorescently labeled antibody to the transferrin receptor (anti-CD71-FITC) to stain RETs, and a fluorescently labeled antibody to label platelets (anti-CD61-PE). After incubation, cells will be stored at 5 °C ± 3 °C until analysis. A propidium iodide solution will be added to each sample before flow cytometric analysis to stain the DNA of micronuclei.

- **Flow Cytometer Calibration**

Methanol-fixed blood from rats infected with *Plasmodium berghei* will be used to configure the flow cytometer before analysis. Whereas MN are relatively rare and exhibit a heterogeneous DNA content, parasitized cells are prevalent and have a homogenous DNA content. These characteristics make them ideal for calibrating the flow cytometer for the micronucleus scoring application.

- **Analysis of Samples**

Samples will be analyzed by flow cytometry. The stained cells are moved past a laser set to provide 488 nm excitation. The fluorescence emitted by each cell is collected by photomultiplier tubes. Using the previously described staining procedure, the propidium iodide-stained DNA of the micronuclei emit a red fluorescence, the anti-CD71-FITC antibody emits a high green fluorescent signal, and platelets are excluded based on their yellow fluorescence.

6. Data Provided

When possible, twenty thousand RET are analyzed per blood sample. In the event of bone marrow toxicity, the number analyzed may be reduced according to Litron's SOPs. The number of normochromatic erythrocytes (NCEs), MN-NCEs, RETs and MN-RETs are provided for each sample. The frequency of MN-RETs and MN-NCEs will be calculated as an indication of genotoxic potential. The % RET will be determined to provide an indication of bone marrow toxicity.

7. Evaluation and Interpretation of Results

No statistical analyses will be performed on the data, other than the calculations indicated above, and the test facility will be responsible for the evaluation and interpretation of results, unless the appropriate box in section B is initialed. If statistical analyses are requested, Litron's SOP for statistical evaluation will be followed and this analysis will include, where applicable: a Shapiro-Wilk test for normality followed by parametric (ANOVA and Dunnett's) or non-parametric (Kruskall Wallis and Wilcoxon Two Sample Test) tests.

8. Records Maintained

If requested in Section B, the original study phase plan, original MicroFlow report, and study-specific records (copies, if applicable) will be transferred to the test facility at the completion of the study phase. Litron will maintain copies of the report, protocol, and study phase plan, along with original study-specific records for two years following completion of the study. After the retention period, Litron will contact the sponsor and study-specific records will either be discarded or sent to the sponsor-requested facility. Electronic copies of some records will be stored off-site (ESL Federal Credit Union, Brighton Henrietta Branch, Rochester, NY) in addition to storage at Litron Laboratories.

9. References

- Albanese R and Middleton BJ (1987) *Mutation Res.* **182**, 323-332.
- Asanami S, Shimono K, Sawamoto O, Kurisu K and Uejima M (1995) *Mutation Res.* **347**, 73-78.
- CSGMT (The Collaborative Study Group for the Micronucleus Test) (1998) *Environ Mol Mutagen.* **32**, 84-100.
- Dertinger SD, Camphausen K, Macgregor JT, Bishop ME, Torous DK, Avlasevich S, Cairns S, Tometsko CR, Menard C, Muanza T, Chen Y, Miller RK, Cederbrant K, Sandelin K, Ponten I, Bolcsfoldi G (2004) *Environ Mol Mutagen.* **44**, 427-35.
- Dertinger SD, Bishop ME, McNamee JP, Hayashi M, Suzuki T, Moore M, Torous DK, and MacGregor JT (2006) *Tox. Sci.* **94**(1), 83-91.
- Dertinger SD, Torous DK, Hall NE, Tometsko CR and Gasiewicz T (2000) *Mutation Res.* **464**, 195-200.
- Dertinger SD, Torous DK, and Tometsko K (1996) *Mutation Res.* **371**, 283-292.
- Dertinger SD, Torous DK, and Tometsko K (January 1999) U.S. Patent No. 5,858,667.
- Dertinger SD, Torous DK, and Tometsko K (August 2000) U.S. Patent No. 6,100,038.
- Hayashi M, MacGregor J, Gatehouse D, Blakey D, Dertinger S, Abramsson-Zetterberg L, Krishna G, Morita T, Russo A, Asano N, Suzuki H, Ohyama W, and Gibson D (2007) *Mutation Res.* **627**, 10-30.
- Hayashi M, Sofuni T and Ishidate M (1983) *Mutation Res.* **121**, 241-247.
- Heddle J, Hite M, Kirkhart B, Mavournin K, MacGregor J, Newell G and Salamone M (1983) *Mutation Res.* **123**, 61-118.
- Holden H, Majeska J and Studwell D (1997) *Mutation Res.* **391**, 87-89.
- Kissling GE, Dertinger SD, Hayashi M, and MacGregor JT (2007) *Mutation Res.* **634**, 235-240.
- MacGregor JT, Bishop ME, McNamee JP, Hayashi M, Asano N, Wakata A, Nakajima M, Saito J, Aidoo A, Moore MM and Dertinger SD (2006) *Tox. Sci.* **94**(1), 92-107
- MacGregor JT, Wehr CM, and Gould DH (1980) *Environ Mutagenesis* **2**, 509-514.
- Salamone M and Heddle J (1983) In: deSerres F (ed.): "Chemical Mutagens, Vol. 8." New York: Plenum, pp.111-149.
- Salamone M, Heddle J, Stuart E and Katz M (1980) *Mutation Res.* **74**, 347-356.
- Schmid W (1975) *Mutation Res.* **31**, 9-15.
- Serke S and Huhn D (1992) *British J. Haematology* **81**, 432-439. Tometsko, Andrew M. (July 1993) U.S. Patent No. 5,229,265.
- Tometsko AM (July 1993) U.S. Patent No. 5,229,265.
- Tometsko AM, Dertinger SD and Torous DK (1995) *Mutation Res.* **334**, 9-18.
- Tometsko AM, Dertinger SD and Torous DK (1993b) *Mutation Res.* **292**, 137-143.
- Tometsko AM, Torous DK and Dertinger SD (1993a) *Mutation Res.* **292**, 129-135.
- Tometsko AM, Torous DK and Dertinger SD (1993c) *Mutation Res.* **292**, 145-153.
- Torous DK, Dertinger SD, Hall NE and Tometsko CR (2000) *Mutation Res.* **465**, 91-99.
- Torous DK, Hall NE, Murante F, Gleason S, Tometsko CR, and Dertinger SD (2003) *Tox. Sci.* **74**, 309-314.
- Witt KL, Livanos E, Kissling GE, Torous DK, Caspary W, Tice RR, and Recio L (2007) *Mutation Res.* In Press.
- Section 4 of the OECD Guidelines for the Testing of Chemicals: Mammalian Erythrocyte Micronucleus Test, Guideline 474 (Adopted 21st July 1997). This guideline states "... any appropriate mammalian species may be used provided it is a species in which the spleen does not remove micronucleated erythrocytes or a species which has shown an adequate sensitivity to detect agents that cause structural or numerical chromosome aberrations."
- Where applicable, GLP regulations for non-clinical laboratory studies as developed by the FDA (21 CFR 58). Please note that the computerized systems utilized for data acquisition, data analysis and report generation have undergone an internal validation guided by FDA GLP regulations. Litron is working towards 21 CFR part 11 compliance.
- Where applicable, Principles of GLP by OECD [C(97)186/FINAL].
- Where applicable, ISO 10993-3: Biological evaluation of medical devices – Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicology (2003-10-15).
- Where applicable, ICH Tripartite Guideline: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, S2A, adopted April 24, 1996.
- Where applicable, ICH Tripartite Guideline: Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, S2B, adopted November 21, 1997.

10. Effective Date: January 1, 2008